KIT and gastrointestinal stromal tumor: CK2 inactivation increased imatinib sensitivity in drug-resistant GIST cells, indicating that combinatorial inhibition of the CK2 and KIT signalling pathway is a rational therapeutic strategy in GISTs, especially in imatinib-resistant GISTs.